IMUNON Announces Leadership Change
12 mars 2024 17h00 HE
|
Imunon, Inc.
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J., March 12, 2024 ...
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
07 sept. 2023 16h30 HE
|
Imunon, Inc.
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) --...
IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023
12 juin 2023 08h30 HE
|
Imunon, Inc.
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel discussion LAWRENCEVILLE, N.J., June 12, 2023 (GLOBE NEWSWIRE) --...
IMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention
08 juin 2023 08h30 HE
|
Imunon, Inc.
Dr. Corinne Le Goff highlights clinical progress across the Company’s pipeline, provides context on the promise of DNA as a therapeutic and a vaccine LAWRENCEVILLE, N.J., June 08, 2023 (GLOBE...
IMUNON CEO Issues Letter to Shareholders
01 mars 2023 08h45 HE
|
Imunon, Inc.
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
27 sept. 2022 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief...